Replay, a new gene therapy business, just introduced Telaria as their newest venture. Recessive dystrophic epidermolysis bullosa is a rare skin condition for which Telaria is developing a gene treatment. It is a genetic disease that makes the skin more susceptible to blisters and other irritations because of a lack of connection between the dermis and epidermis.
Related: Research ward for pharma partnerships to be established in Shanghai’s Maternity and Infant Hospital
Telaria will use the herpes simplex virus’s (HSV) greater potential to deliver a gene therapy. Replay has a “hub-and-spoke” corporate structure, in which it creates its own technologies and discovers therapeutic areas that at least one of these platforms may address. Replay then creates businesses that are specialised in various therapeutic fields.
Read More from MedCityNews
